Cleerly is a digital healthcare company headquartered in Denver, Colorado, that develops an artificial intelligence platform for the diagnosis and management of heart disease. The company's FDA-cleared technology analyzes coronary computed tomography angiography (CCTA) scans to detect, characterize and quantify atherosclerotic plaque non-invasively.
Cleerly's clinical thesis is that heart disease can be identified and managed earlier through AI-driven phenotyping of coronary arteries, moving cardiac care from a reactive model centered on symptoms and events toward proactive, precision risk assessment. Its analyses provide clinicians with detailed plaque characterization to inform treatment decisions.
The company was founded in 2017 by Dr. James K. Min, a cardiologist and cardiac imaging researcher who serves as CEO. Cleerly has built its platform around large volumes of coronary CT data and clinical validation studies, and has secured multiple FDA clearances for its solutions.
Cleerly is among the most heavily funded companies in AI-driven cardiac imaging. It raised a $223 million Series C led by T. Rowe Price and Fidelity in 2022, followed by a $106 million Series C extension in December 2024 led by Insight Partners with participation from Battery Ventures and existing investors. The extension was raised at the prior round's pricing, supporting continued commercial expansion.
The company operates in a competitive but high-stakes market, given that cardiovascular disease remains a leading cause of death globally. Cleerly's combination of FDA clearances, clinical evidence and substantial capital positions it as a leading independent player in AI-assisted coronary diagnostics.